RxDoctor Payments Data

Scott Acosta, MD

Internal Medicine · Marrero, LANPI 1023018199

Payments from drug & device makers

$1,641in general payments, 2019–2025

Across 93 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$582
  • Pfizer$214
  • AbbVie$196
  • Boston Scientific$111
  • Novartis$86
  • Amgen$80
  • plus $372 from 14 others

What the payments were for

  • Food & beverage$1,62699%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,641 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$33,212
Medicare patients
200
Services billed
442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide211$282,914
EliquisApixaban233$186,004
MounjaroTirzepatide91$109,548
FarxigaDapagliflozin Propanediol106$79,442
JanuviaSitagliptin Phosphate60$72,601
JardianceEmpagliflozin80$71,119
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$60,456
XareltoRivaroxaban33$36,185
MyrbetriqMirabegron34$31,855
TrulicityDulaglutide22$25,171
EntrestoSacubitril/Valsartan19$18,753
LinzessLinaclotide29$17,439
Breo ElliptaFluticasone/Vilanterol26$14,115
Lantus SolostarInsulin Glargine,hum.Rec.Anlog108$12,270
BrilintaTicagrelor17$11,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$34$282,914211 claims
PfizerEliquis$214$186,004233 claims
Boehringer IngelheimJardiance, Stiolto Respimat$15$77,62794 claims
GSKTrelegy Ellipta, Breo Ellipta$582$74,571105 claims
MerckJanuvia$68$72,60160 claims
AbbVieLinzess, Synthroid$196$22,76199 claims
NovartisEntresto$86$18,75319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →